Adaptive Biotechnologies Corporation Common Stock (ADPT) Financials
Key financial figures for Adaptive Biotechnologies Corporation Common Stock (Q3 2026).
Adaptive reported Q3 2026 revenue of $83.9 million, down 11% year over year against a Genentech-inflated comparison, while MRD revenue rose 28% to $72.6 million and the company reported positive net income and free cash flow. Total revenue was $83.9 million, an 11% decrease from $94.0 million in Q3 2025; excluding revenue under the Genentech Agreement, which produced none this quarter, revenue rose 39%. MRD revenue was $72.6 million, up 28% from $56.8 million (44% excluding milestones per the company), and clonoSEQ tests delivered rose 46% to 39,587. MRD segment Adjusted EBITDA (non-GAAP) was $15.1 million versus $7.0 million a year earlier; total company Adjusted EBITDA was $14.3 million versus $28.0 million, when Genentech revenue was still in the base. On the outlook: Full year 2026 MRD revenue guidance raised to $276 million to $286 million (30% to 35% growth) from $268 million to $278 million; full year total company operating expenses, including cost of revenue, expected at approximately $350 million, updated from $350 million to $355 million; no revenue guidance for Immune Medicine. Figures are for Q3 2026, as Adaptive Biotechnologies Corporation reported them.
- Revenue
- $84M
- Net Income
- $3M
- EPS
- $0.02
- Total Assets
- $683M
- Operating Cash Flow
- $10M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $84M | $3M | $0.02 | -0.54% | $8M |
| Q2 FY2026 | $72M | -$40M | -$0.25 | -22.04% | -$8M |
| Q1 FY2026 | $71M | -$20M | -$0.13 | -27.1% | -$10M |
| Q4 FY2025 | $72M | -$14M | -$0.09 | -17.82% | $1M |
| Q3 FY2025 | $94M | $10M | $0.06 | 10.95% | -$8M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $277M | -$59M | -$0.39 | -20.62% | -$49M |
| FY2024 | $179M | -$159M | -$1.08 | -90.83% | -$99M |
| FY2023 | $170M | -$225M | -$1.56 | -133.33% | -$167M |
Frequently asked questions
What was Adaptive Biotechnologies Corporation's revenue last quarter?
Adaptive Biotechnologies Corporation reported revenue of $83.9 million for Q3 FY2026, down 10.7% from the same period a year earlier.
Is Adaptive Biotechnologies Corporation profitable?
Yes. Adaptive Biotechnologies Corporation reported net income of $2.9 million for Q3 FY2026, a net margin of 3.43% on revenue.
How has Adaptive Biotechnologies Corporation's margin trended?
Operating margin was -0.54% in Q3 FY2026, compared with 10.95% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Adaptive Biotechnologies Corporation generate?
Adaptive Biotechnologies Corporation generated free cash flow of $7.7 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Adaptive Biotechnologies Corporation Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.